Plasma exchange in kidney transplantation: Still a valuable option for nephrotic syndrome recurrence

被引:1
作者
Peruzzi, Licia [1 ]
Albiani, Roberto [2 ]
Giancaspero, Karol [2 ]
机构
[1] Citta Salute & Sci Torino, Pediat Nephrol Unit, Regina Margherita Childrens Hosp, Piazza Polonia 94, I-10126 Turin, Italy
[2] Citta Salute & Sci Torino, Apheresis Unit, Regina Margherita Childrens Hosp, Turin, Italy
关键词
Plasmapheresis; Kidney transplantation; Nephrotic syndrome; Post transplant recurrence; Recurrent Focal Segmental; Glomerulosclerosis; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; PERMEABILITY FACTORS; STEROID-RESISTANT; MYCOPHENOLATE-MOFETIL; THERAPEUTIC APHERESIS; HIGH-RISK; RITUXIMAB; PLASMAPHERESIS; CHILDREN; REMOVAL;
D O I
10.1016/j.transci.2017.07.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
About 30% of the cases of steroid resistant nephrotic syndrome display a genetically determined disease and will not recur after kidney transplant; the other cases with fully or partially immunological pathogenesis display a high risk of post transplant recurrence. Although lots of studies were carried out in the last 50 years the pathogenetic mechanism is still obscure and the therapeutic approach mostly empirical. The cornerstones principles of the therapies are based on removal of a still undefined "permeability factor" through plasma-exchange or other apheresis techniques and inhibition of its synthesis by the immunological system through different drugs. The probability of successfully inducing persistant remission is nowadays around 30% through the different schemes experimented so far which mostly include plasmapheresis. Rituximab in the last years has significantly increased the efficacy of the treatments. Non responders are rapidly evolving to graft loss and will most probably recur also in subsequent transplant. Apart from genetics no other risk factors are predictive for recurrence. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:525 / 530
页数:6
相关论文
共 52 条
[1]  
Abel JJ, 1914, J PHARMACOL EXP THER, VV, P166
[2]   Late steroid resistance in childhood nephrotic syndrome: do we now know more than 40 years ago? [J].
Akchurin, Oleh M. ;
Kaskel, Frederick J. .
PEDIATRIC NEPHROLOGY, 2013, 28 (08) :1157-1160
[3]   Reasons why therapeutic apheresis should belong to nephrology [J].
Anaya Fernandez-Lomana, F. .
NEFROLOGIA, 2011, 31 (04) :379-381
[4]   Altered activity of plasma hemopexin in patients with minimal change disease in relapse [J].
Bakker, WW ;
van Dael, CML ;
Pierik, LJWM ;
van Wijk, JAE ;
Nauta, J ;
Borghuis, T ;
Kapojos, JJ .
PEDIATRIC NEPHROLOGY, 2005, 20 (10) :1410-1415
[5]   Mycophenolate Mofetil Following Rituximab in Children With Steroid-Resistant Nephrotic Syndrome [J].
Basu, Biswanath ;
Mahapatra, T. K. S. ;
Mondal, Nirmal .
PEDIATRICS, 2015, 136 (01) :E132-E139
[6]  
Bierzynska A, 2017, KIDNEY INT
[7]   TNFα pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and β3 integrin activation [J].
Bitzan, Martin ;
Babayeva, Sima ;
Vasudevan, Anil ;
Goodyer, Paul ;
Torban, Elena .
PEDIATRIC NEPHROLOGY, 2012, 27 (12) :2217-2226
[8]  
Bromberg JS., 2009, AM J TRANSPL, V9, P1
[9]  
Bruce C, 2010, APHERESIS PRINCIPLES, P95
[10]   Intensive and Prolonged Treatment of Focal and Segmental Glomerulosclerosis Recurrence in Adult Kidney Transplant Recipients: A Pilot Study [J].
Canaud, G. ;
Zuber, J. ;
Sberro, R. ;
Royale, V. ;
Anglicheau, D. ;
Snanoudj, R. ;
Gaha, K. ;
Thervet, E. ;
Lefrere, F. ;
Cavazzana-Calvo, M. ;
Noel, L. -H. ;
Mejean, A. ;
Legendre, Ch. ;
Martinez, F. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (05) :1081-1086